Effect of pre- and post-surgery treatment with risedronate on trabecular bone loss in ovariectomized rats

Experimental Animals

Volumn 55, Issue 5, 2006, Pages 457-466

  Iwamoto, Jun ^a   Takeda, Tsuyoshi ^a   Sato, Yoshihiro ^b   Shen, Chwan Li ^c   Yeh, James K ^d  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Mitate Hospital   (Japan)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^d WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

Bone turnover; Cancellous osteopenia; Ovariectomy; Pretreatment; Risedronate

Indexed keywords

RISEDRONIC ACID;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; BONE TURNOVER; CONTROLLED STUDY; EARLY INTERVENTION; FEMALE; LOW DRUG DOSE; NONHUMAN; OSTEOMETRY; OSTEOPENIA; OVARIECTOMY; POSTOPERATIVE PERIOD; RAT; RAT STRAIN; TRABECULAR BONE; TREATMENT DURATION;

ABSORPTIOMETRY, PHOTON; ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; BONE RESORPTION; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; FEMALE; FEMUR; FLUORESCEINS; IMAGE PROCESSING, COMPUTER-ASSISTED; OVARIECTOMY; POSTOPERATIVE CARE; PREOPERATIVE CARE; RATS; RATS, SPRAGUE-DAWLEY; TIBIA;

EID: 33750999081     PISSN: 13411357     EISSN: 13411357     Source Type: Journal    
DOI: 10.1538/expanim.55.457     Document Type: Article

References (17)

1. Bone, H.G., Hosking, D., Devogelaer, J.P., Tucci, J.R., Emkey, R.D., Tonino, R.P., Rodriguez-Portales, J.A., Downs, R.W., Gupta, J., Santora, A.C., and Liberman, U.A.; Alendronate Phase III Osteoporosis Treatment Study Group. 2004. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 350: 1189-1199.
2. Chen, Q., Kaji, H., Iu, M.F., Nomura, R., Sowa, H., Yamauchi, M., Tsukamoto, T., Sugimoto, T., and Chihara, K. 2003. Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects. J. Clin. Endocrinol. Metab. 88: 4655-4658.
3. Cranney, A., Guyatt, G., Griffith, L., Wells, G., Tugwell, P., and Rosen, C.; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. 2002. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr. Rev. 23: 570-578.
4. Erben, R.G. 1997. Embedding of bone samples in methylmethacrylate: an improved method suitable for bone histomorphometry, histochemistry, and immunohistochemistry. J. Histochem. Cytochem. 45: 307-313.
5. 3. J. Bone Miner. Res. 17: 1498-1511.
6. Fleisch, H. 1998. Bisphosphonates: Mechanism of action. Endocr. Rev. 19: 80-100.
7. Gambacciani, M., Spinetti, A., Taponeco, F., Cappagli, B., Maffei, S., Manetti, P., Piaggesi, L., and Fioretti, P. 1994. Bone loss in perimenopausal women: a longitudinal study. Maturitas 18: 191-197.
8. Khan, A.A. and Syed, Z. 2004. Bone densitometry in premenopausal women: synthesis and review. J. Clin. Densitom. 7: 85-92.
9. Leu, C.T., Luegmayr, E., Freedman, L.P., Rodan, G.A., and Reszka, A.A. 2005. Relative binding affinities of bisphosphonates for human, bone and relationship to antiresorptive efficacy. Bone (Online publication).
10. 2 and risedronate administration on cancellous bone in older female rats. Bone 15: 489-496.
11. Mashiba, T., Hirano, T., Turner, C.H., Forwood, M.R., Johnston, C.C., and Burr, D.B. 2000. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J. Bone Miner. Res. 15: 613-620.
12. Mellstrom, D.D., Sorensen, O.H., Goemaere, S., Roux, C., Johnson, T.D., and Chines, A.A. 2004. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif. Tissue Int. 75: 462-468.
13. Nancollas, G.H., Tang, R., Phipps, R.J., Henneman, Z., Gulde, S., Wu, W., Mangood, A., Russell, R.G., and Ebetino, F.H. 2005. Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone (Online publication).
14. 2. J. Bone. Miner. Metab. 22: 404-414.
15. Parfitt, A.M., Drezner, M.K., Glorieux, F.H., Kanis, J.A., Malluche, H., Meunier, P.J., Ott, S.M., and Recker, R.R. 1987. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASMBR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2: 595-610.
16. Prakasam, G., Yeh, J.K., Chen, M.M., Castro-Magana, M., Liang, C.T., and Aloia, J.F. 1999. Effects of growth hormone and testosterone on cortical bone formation and bone density in aged orchiectomized rats. Bone 24: 491-497.
17. Ravn, P., Bidstrup, M., Wasnich, R.D., Davis, J.W., McClung, M.R., Balske, A., Coupland, C., Sahota, O., Kaur, A., Daley, M., and Cizza, G. 1999. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann. Intern. Med. 131: 935-942.